Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	20 people with chronic abacterial prostatitis In review	Adverse effects with alfuzosin 2.5 mg three times daily with placebo
RCT 3-armed trial	70 men with chronic abacterial prostatitis In review	Adverse effects with alfuzosin 5 mg twice daily for 6 months with placebo
RCT	86 men with chronic abacterial prostatitis In review	Treatment-related adverse effects 14 weeks 18/43 (42%) with terazosin 9/43 (21%) with placebo	P = 0.04	Effect size not calculated	placebo
RCT	86 men with chronic abacterial prostatitis In review	Dizziness 14 weeks 7/43 (16%) with terazosin 2/43 (5%) with placebo	Significance not assessed
RCT	86 men with chronic abacterial prostatitis In review	Asthenia 14 weeks 7/43 (16%) with terazosin 3/43 (7%) with placebo	Significance not assessed
3-armed trial	90 men with chronic abacterial prostatitis	Adverse effects 12/30 (40%) with doxazosin 4 mg daily 7/30 (23%) with placebo	Significance not assessed
3-armed trial	90 men with chronic abacterial prostatitis	Dizziness 3/30 (10%) with doxazosin 4 mg daily 2/30 (7%) with placebo	Significance not assessed
3-armed trial	90 men with chronic abacterial prostatitis	Postural hypotension 3/30 (10%) with doxazosin 4 mg daily 1/30 (3%) with placebo	Significance not assessed
3-armed trial	90 men with chronic abacterial prostatitis	Gastrointestinal complaints 2/30 (7%) with doxazosin 4 mg daily 2/30 (7%) with placebo	Significance not assessed
RCT 4-armed trial	196 men with chronic abacterial prostatitis	Adverse effects with tamsulosin with no tamsulosin Absolute results not reported	P >0.2		Not significant
RCT	272 men with prostatitis for at least 2 years, and with no previous treatment with an alpha-blocker	Adverse effects 38/138 (28%) with alfuzosin 39/134 (29%) with placebo	P = 0.79		Not significant